The United States of America, As Represented by the Secretary, Department of Health and Human Services

US Government As Represented by the Secretary of the Army

Beth Israel Deaconess Medical Center, Inc.

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Kayvon Modjarrad

John R Mascola

Barney S Graham

Michael Gordon Joyce

Masaru Kanekiyo

Wing-Pui Kong

Wei Shi

Lingshu Wang

Dan H Barouch

Nelson L Michael

Rajeshwer Singh Sankhala

Vincent Dussupt

Gina Donofrio

Richard G Jarman, Iii

Shelly Krebs

Gordon Joyce

Kathryn Elaine Stephenson

The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.

Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination

Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.

Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use

Growing community of inventors

Bethesda, MD, United States of America

Kayvon Modjarrad